|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TMCC1 |
Gene summary for TMCC1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TMCC1 | Gene ID | 23023 |
| Gene name | transmembrane and coiled-coil domain family 1 | |
| Gene Alias | TMCC1 | |
| Cytomap | 3q22.1 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | O94876 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 23023 | TMCC1 | CCI_1 | Human | Cervix | CC | 1.80e-12 | 1.42e+00 | 0.528 |
| 23023 | TMCC1 | CCI_2 | Human | Cervix | CC | 1.31e-13 | 1.36e+00 | 0.5249 |
| 23023 | TMCC1 | CCI_3 | Human | Cervix | CC | 1.11e-38 | 2.01e+00 | 0.516 |
| 23023 | TMCC1 | HTA11_3410_2000001011 | Human | Colorectum | AD | 3.61e-11 | -5.30e-01 | 0.0155 |
| 23023 | TMCC1 | HTA11_866_3004761011 | Human | Colorectum | AD | 7.41e-03 | -3.40e-01 | 0.096 |
| 23023 | TMCC1 | A002-C-010 | Human | Colorectum | FAP | 9.47e-03 | -2.17e-02 | 0.242 |
| 23023 | TMCC1 | A001-C-207 | Human | Colorectum | FAP | 3.59e-03 | -1.46e-01 | 0.1278 |
| 23023 | TMCC1 | A015-C-203 | Human | Colorectum | FAP | 1.44e-31 | -5.14e-01 | -0.1294 |
| 23023 | TMCC1 | A015-C-204 | Human | Colorectum | FAP | 1.01e-03 | -2.64e-01 | -0.0228 |
| 23023 | TMCC1 | A014-C-040 | Human | Colorectum | FAP | 5.32e-07 | -5.08e-01 | -0.1184 |
| 23023 | TMCC1 | A002-C-201 | Human | Colorectum | FAP | 1.60e-12 | -2.50e-01 | 0.0324 |
| 23023 | TMCC1 | A002-C-203 | Human | Colorectum | FAP | 4.04e-02 | -7.23e-02 | 0.2786 |
| 23023 | TMCC1 | A001-C-119 | Human | Colorectum | FAP | 1.18e-04 | -1.41e-01 | -0.1557 |
| 23023 | TMCC1 | A001-C-108 | Human | Colorectum | FAP | 1.43e-14 | -2.60e-01 | -0.0272 |
| 23023 | TMCC1 | A002-C-205 | Human | Colorectum | FAP | 1.55e-20 | -3.31e-01 | -0.1236 |
| 23023 | TMCC1 | A001-C-104 | Human | Colorectum | FAP | 2.11e-03 | -1.49e-01 | 0.0184 |
| 23023 | TMCC1 | A015-C-005 | Human | Colorectum | FAP | 3.04e-03 | -2.22e-01 | -0.0336 |
| 23023 | TMCC1 | A015-C-006 | Human | Colorectum | FAP | 8.40e-17 | -4.28e-01 | -0.0994 |
| 23023 | TMCC1 | A015-C-106 | Human | Colorectum | FAP | 5.96e-15 | -3.00e-01 | -0.0511 |
| 23023 | TMCC1 | A002-C-114 | Human | Colorectum | FAP | 1.15e-18 | -3.60e-01 | -0.1561 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00161977 | Cervix | CC | endosomal transport | 48/2311 | 230/18723 | 1.65e-04 | 1.97e-03 | 48 |
| GO:00160506 | Cervix | CC | vesicle organization | 54/2311 | 300/18723 | 2.71e-03 | 1.85e-02 | 54 |
| GO:00482851 | Cervix | CC | organelle fission | 78/2311 | 488/18723 | 9.70e-03 | 4.79e-02 | 78 |
| GO:0016197 | Colorectum | AD | endosomal transport | 90/3918 | 230/18723 | 1.88e-10 | 1.73e-08 | 90 |
| GO:0016050 | Colorectum | AD | vesicle organization | 101/3918 | 300/18723 | 1.65e-07 | 7.17e-06 | 101 |
| GO:0007032 | Colorectum | AD | endosome organization | 33/3918 | 82/18723 | 5.30e-05 | 9.01e-04 | 33 |
| GO:0007029 | Colorectum | AD | endoplasmic reticulum organization | 31/3918 | 87/18723 | 1.08e-03 | 1.00e-02 | 31 |
| GO:00160503 | Colorectum | FAP | vesicle organization | 74/2622 | 300/18723 | 5.16e-07 | 2.66e-05 | 74 |
| GO:00161973 | Colorectum | FAP | endosomal transport | 56/2622 | 230/18723 | 1.79e-05 | 4.53e-04 | 56 |
| GO:00070323 | Colorectum | FAP | endosome organization | 20/2622 | 82/18723 | 8.23e-03 | 4.82e-02 | 20 |
| GO:00161974 | Colorectum | CRC | endosomal transport | 49/2078 | 230/18723 | 5.07e-06 | 2.05e-04 | 49 |
| GO:00160504 | Colorectum | CRC | vesicle organization | 57/2078 | 300/18723 | 3.36e-05 | 8.57e-04 | 57 |
| GO:00070324 | Colorectum | CRC | endosome organization | 18/2078 | 82/18723 | 3.37e-03 | 2.88e-02 | 18 |
| GO:001605014 | Esophagus | ESCC | vesicle organization | 211/8552 | 300/18723 | 2.85e-18 | 2.87e-16 | 211 |
| GO:001619715 | Esophagus | ESCC | endosomal transport | 168/8552 | 230/18723 | 2.28e-17 | 1.93e-15 | 168 |
| GO:00482853 | Esophagus | ESCC | organelle fission | 301/8552 | 488/18723 | 4.64e-13 | 2.12e-11 | 301 |
| GO:000702914 | Esophagus | ESCC | endoplasmic reticulum organization | 65/8552 | 87/18723 | 3.28e-08 | 6.08e-07 | 65 |
| GO:000703214 | Esophagus | ESCC | endosome organization | 61/8552 | 82/18723 | 1.13e-07 | 1.85e-06 | 61 |
| GO:00161975 | Liver | NAFLD | endosomal transport | 41/1882 | 230/18723 | 2.02e-04 | 3.53e-03 | 41 |
| GO:00160505 | Liver | NAFLD | vesicle organization | 50/1882 | 300/18723 | 2.42e-04 | 4.06e-03 | 50 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TMCC1 | SNV | Missense_Mutation | novel | c.1217N>A | p.Gly406Glu | p.G406E | O94876 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-A7-A2KD-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
| TMCC1 | SNV | Missense_Mutation | novel | c.1900N>A | p.Leu634Ile | p.L634I | O94876 | protein_coding | tolerated(0.08) | benign(0.188) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TMCC1 | SNV | Missense_Mutation | c.1173N>G | p.Asp391Glu | p.D391E | O94876 | protein_coding | tolerated(0.1) | probably_damaging(0.992) | TCGA-BH-A0AW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD | |
| TMCC1 | SNV | Missense_Mutation | novel | c.1835N>G | p.Val612Gly | p.V612G | O94876 | protein_coding | deleterious(0.01) | probably_damaging(0.95) | TCGA-BH-A0BO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TMCC1 | SNV | Missense_Mutation | c.1094N>C | p.Val365Ala | p.V365A | O94876 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD | |
| TMCC1 | SNV | Missense_Mutation | c.1045N>C | p.Gly349Arg | p.G349R | O94876 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EW-A1PD-01 | Breast | breast invasive carcinoma | Male | <65 | I/II | Chemotherapy | docetaxel | SD | |
| TMCC1 | deletion | Frame_Shift_Del | novel | c.354delN | p.Thr119GlnfsTer27 | p.T119Qfs*27 | O94876 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| TMCC1 | SNV | Missense_Mutation | rs148011506 | c.1321N>A | p.Ala441Thr | p.A441T | O94876 | protein_coding | tolerated(0.24) | benign(0.006) | TCGA-VS-A8EH-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
| TMCC1 | deletion | Frame_Shift_Del | novel | c.1840delN | p.Leu614SerfsTer2 | p.L614Sfs*2 | O94876 | protein_coding | TCGA-C5-A1BK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | ||
| TMCC1 | SNV | Missense_Mutation | novel | c.146N>A | p.Gly49Asp | p.G49D | O94876 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.998) | TCGA-A6-2672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |